1464910-32-4
Chemical Structure
JG26
- CAS No.: 1464910-32-4
- Formula:C19H22Br2N4O6S
- Molecular Weight:594.27
IUPAC Name: (R)-2-((4-((3,5-dibromobenzyl)oxy)phenyl)sulfonamido)-N-hydroxy-5-ureidopentanamide
InChIKey: QTXVPJOTKLUYMQ-QGZVFWFLSA-N
SMILES: O=C([C@@H](CCCNC(N)=O)NS(=O)(C1=CC=C(C=C1)OCC2=CC(Br)=CC(Br)=C2)=O)NO
Biological Activity: JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JG26 | 98.14% | JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Gentili V, et al. JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro. Pharmacol Rep. 2025 Feb;77(1):260-273. [Content Brief]
- [2]. Zocchi MR, et al. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology. 2015 Dec 29;5(5):e1123367. [Content Brief]
- [3]. Cuffaro D, et al. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. ACS Med Chem Lett. 2021 Oct 8;12(11):1787-1793. [Content Brief]
- [4]. Li K, et al. Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer. J Exp Clin Cancer Res. 2024 Feb 27;43(1):59. [Content Brief]
- [5]. Kawai T, et al. Pharmacological Inhibition of ADAM17 by a Human-Cross Reactive Antibody and Selective Inhibitor JG26 Prevents Vascular Fibrosis Induced by Angiotensin II in vivo and in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36(suppl_1): A557-A557.
- [6]. Doretta Cuffaro, et al. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. ACS Med Chem Lett. 2021 Oct 8;12(11):1787-1793. [Content Brief]
Keywords
